Proteon Therapeutics
Waltham
About Proteon Therapeutics
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $192.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2021)
- Ticker: nasdaq:PRTO
- Website: proteontherapeutics.com
- Phone: 7818900102
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/proteon-therapeutics-182757 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.